
    
      This will be a randomised, open-label, two-period, single dose, crossover bioequivalence
      study in healthy subjects under fasting conditions to assess bioequivalence of 1 x 60 mg
      capsule methylphenidate compared to 2 x 30 mg capsules methylphenidate. Pharmacokinetics and
      safety will be assessed.
    
  